Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8780925 | Gynecologic Oncology Reports | 2018 | 4 Pages |
Abstract
Binimetinib may present a new treatment option for hormone- and chemotherapy-resistant LGSOC harboring KRAS mutations.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Chanhee Han, Stefania Bellone, Luca Zammataro, Peter E. Schwartz, Alessandro D. Santin,